GFAP and Alzheimer disease: As a cytoskeletal component of astrocytes, GFAP could serve as a promising biomarker reflecting astrocytic activation and proliferation during the neurodegenerative processes, including AD, particularly in its earliest stages (Chatterjee et al., 2021; Verberk et al., 2021).